Mortgage rates today near 6% as Fed meeting kicks off; housing stocks mixed

Mortgage rates today near 6% as Fed meeting kicks off; housing stocks mixed

New York, Jan 27, 2026, 06:49 EST — Premarket

  • 30-year mortgage rates remain near the low-6% mark in the most recent daily data.
  • Traders are zeroing in on the Fed’s policy stance and the trajectory of long-term Treasury yields, which directly impact mortgage rates.
  • Housing-related shares showed a mixed picture in the latest quotes, while homebuilders slipped lower.

U.S. mortgage rates held steady early Tuesday, lingering near the low-6% mark. Investors are bracing for a Federal Reserve policy meeting that might shift the outlook on borrowing costs moving forward.

That’s crucial since small shifts add up fast at current prices. Even a fraction of a percentage point can swing monthly payments enough to nudge hesitant buyers either into the market or out, just as the industry eyes the upcoming spring surge.

Rates remain near the recent lows highlighted in last week’s surveys, following a prolonged period of mortgage costs that were tough on buyers and those looking to refinance. 1

Under the surface of daily chatter, Optimal Blue’s Mortgage Market Indices reveal the real story. Their latest reading puts conforming 30-year rates at 6.088%, based on “locked” loans. The firm notes these indices come from actual lock data, refreshed every night with the previous day’s activity. 2

Bankrate’s latest survey showed the average 30-year fixed mortgage rate at 6.20% on Monday, with the 15-year coming in at 5.57% and the 5/1 adjustable-rate mortgage at 5.48%. (A basis point equals 0.01 percentage point; APR includes the interest rate plus certain fees.) Sean Salter, associate professor of finance at Middle Tennessee State University, noted, “Although the Fed is widely expected to hold policy rates steady, uncertainty around forward guidance – along with increased geopolitical risk – will continue to place upward pressure on long-term rates.” 3

Long-term yields are carrying the weight. The U.S. Treasury 10-year yield closed Monday at 4.22%, slipping just a notch from Friday’s 4.24%. It’s a modest drop but directly impacts the funding costs that lenders hedge and then pass on to borrowers. 4

In housing-related trades, the iShares U.S. Home Construction ETF slipped 0.6% to $104.57. Lennar dipped 1.1%, landing at $110.58. Rocket Companies nudged up 0.6%, hitting $21.21, but loanDepot dropped 2.3% to $2.58. The iShares MBS ETF, which tracks agency mortgage-backed securities, ticked higher by 0.2% to $95.75.

Mortgage News Daily’s daily index reported the 30-year fixed rate at 6.17% on Monday, slipping 2 basis points from the previous reading. This highlights just how narrow the range has remained. 5

Still, that calm can shatter quickly. If the Fed turns hawkish—even without hiking its benchmark rate—Treasury yields can spike, dragging mortgage rates up with them. Softer data might pull rates down, but the relationship rarely moves in a straight line.

Investors and borrowers are turning their attention to the Fed’s announcement and press conference on Wednesday. Ahead of that, Tuesday brings key housing data with home price reports and consumer confidence figures. On Wednesday morning, MBA mortgage applications will also be released. 6

Stock Market Today

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

7 February 2026
Applied Digital Corporation shares jumped 25.52% Friday to $34.95, then slipped to $34.60 after hours. The company reported fiscal Q2 revenue up 250% to $126.6 million and signed leases for 600 MW of data center capacity in North Dakota. Applied Digital broke ground on a new 430‑MW campus in the southern U.S. in January. Financing includes a $100 million promissory note with 8% interest, paid in kind.
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

7 February 2026
Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
XRP price dips near $1.88 after Monday bounce; Ripple’s Saudi bank pact in focus as Fed decision nears
Previous Story

XRP price dips near $1.88 after Monday bounce; Ripple’s Saudi bank pact in focus as Fed decision nears

Nvidia’s $2 billion CoreWeave bet shakes up AI stocks before Microsoft earnings
Next Story

Nvidia’s $2 billion CoreWeave bet shakes up AI stocks before Microsoft earnings

Go toTop